SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
latest_posts
- 1
Artemis moon mission breaks record for distance from Earth - 2Hamas Navy head, engineer of Khan Yunis tunnel network killed in Gaza, IDF confirms
- 3Turkey’s intel chief lays out country’s vision for Middle East, world
- 4Oil, energy and food: Which countries in Europe are most exposed to higher food prices?
- 5Affordable Care Act enrollment is slightly ahead of last year, despite expiring subsidies
- Building a Maintainable Closet: Individual Excursions in Moral Style
- German foreign minister backs abandoning EU's unanimity principle
- EU calls on Western Balkans to step up reforms for membership
- U.S. to drop childhood vaccine recommendations as it looks to Denmark, Washington Post reports
- Artemis II astronauts find hidden Easter eggs as they close in on the moon
- Private sector revives the climate disaster database Trump tried to squash
- Wolf Bites Woman in Shocking Attack at Busy Shopping Center
- Picking the Right Home Machines: A Commonsense Aide
- Grass Care Administrations for a Wonderful, Sound Yard
